Mölnlycke Health Care expands investment in Tamer Mölnlycke Care joint venture

The bond was more than five times oversubscribed with an orderbook of over EUR 2,700M at its peak. There was strong and widespread demand from leading investors in Germany, Austria and Switzerland 32%, UK & Ireland 28%, Nordics 18%, France 12% and Other 10%. Asset Managers represented 87% of investors, followed by Insurance and Pension Funds with 9% and Banks with 4%. The proceeds will be used to finance a Tender Offer of Mölnlycke’s outstanding EUR 500M notes maturing in 2025 as well as for general corporate purposes. The bond further extends the duration of Mölnlycke’s well-spread debt maturity profile. The bond will be listed on the Euro MTF market of the Luxembourg Stock Exchange. BNP Paribas, ING, JP Morgan and SEB acted as joint bookrunners for the transaction.

The Tamer Mölnlycke Care joint venture was initiated in 2021 with the agreement to develop a customised surgical procedure tray factory in Saudi Arabia, with first production expected in Q4 2024. The increased investment allows for an expansion in the range of Mölnlycke products manufactured and distributed in the country and to the neighbouring region. Adding drapes and gowns, emollient range and selected wound care products to the offering allows more healthcare professionals and patients in the region to benefit from Mölnlycke products and solutions. Zlatko Rihter, CEO, Mölnlycke Health Care comments “To ensure we meet customer demand, geographical expansion is a strategic priority for Mölnlycke Health Care. Increased investment in our existing long-term partnership with Tamer Group will importantly enable healthcare professionals and patients in Saudi Arabia access to our quality products and solutions helping to improve outcomes, and is a step closer to realising the potential of this rapidly growing healthcare market.” Speaking on behalf of Tamer Group, Chairman Ayman Tamer adds “This investment is key to enabling future growth in the region as outlined in the Saudi Vision 2030 - supporting the regional healthcare ecosystem, including exporting goods to the Middle East and Africa region, whilst developing local skills and expertise.” Mahmoud Wagih, CEO, Tamer Mölnlycke Care comments “I am delighted to lead this business where Mölnlycke and Tamer will build a strong, long-term successful joint venture, bringing superior health care solutions to our region.” The Tamer Mölnlycke Care joint venture is a long-term agreement between two organisations who have been working in partnership over the past decade; and are committed to meeting customer demand in the evolving healthcare landscape of Saudi Arabia and the wider region. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke   Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.  Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com   

Gothenburg 12 April 2024: Mölnlycke, a world leading MedTech company specialised in wound care and wound management, announced today it signed an agreement to acquire P.G.F. Industry Solutions GmbH, the Austrian manufacturer of Granudacyn wound cleansing and moisturising solutions. Mölnlycke and P.G.F. have worked together for five years on the manufacturing and distribution of Granudacyn, a range of solution and gel products intended for use in the cleansing, irrigation and moisturisation of various wound types. The high quality and composition of Granudacyn ensures good biocompatibility, allowing it to be effectively used on a broad range of tissues in burns, as well as acute and chronic wounds. Mölnlycke currently distributes Granudacyn in over 50 countries around the world. “With an ageing population in combination with increased chronic wounds, such as diabetic foot ulcers or venous leg ulcers, it is our obligation to help ease the burden of wounds on national healthcare regimes” says Zlatko Rihter, CEO of Mölnlycke Health Care. “The acquisition of P.G.F. and its state-of-the-art manufacturing plant, will allow Mölnlycke to aggressively expand our Granudacyn business to improve the lives of even more patients.” “I’m excited for P.G.F. to become part of Mölnlycke and for the team to continue to manufacture products that support Mölnlycke’s Wound Care mission to help free patients from the burden of wounds” says Peter Fritz, P.G.F. founder and CEO, who will continue to lead this team and manufacturing process from P.G.F.’s Austria headquarters. Closure is expected after certain milestones are reached and will be communicated separately. For more information, please contact: Jennifer Doak Global Communications Director Wound Care Email: jennifer.doak@molnlycke.com Phone: +1 678 206 6179 About Mölnlycke® Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com About P.G.F. Industry Solutions P.G.F. Industry Solutions was founded in 2005 by Peter Fritz to develop and produce ecologically compatible hypochlorous acid based products to protect the user and their environment. The company is founded on more than 30 years of experience in research, development, production, and worldwide distribution of medical and measurement products. P.G.F. employs approximately 25 employees and is headquartered in Elixhausen, Austria. www.veriforte.com.

The facility is backed by a group of seven leading global and regional banks, well diversified to match Mölnlycke’s geographical footprint. The banks are BNP, Danske Bank, HSBC, ING, JP Morgan, Nordea and SEB as mandated lead arrangers. SEB acted as the coordinator, documentation agent and facility agent for the transaction. For more information, please contact:  Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560 About Mölnlycke   Mölnlycke is a world-leading medical products and solutions company that equips healthcare professionals to achieve the best patient, clinical and economic outcomes. The core business is within the four Business Areas Wound Care, Operating Room Solutions (ORS), Gloves and Antiseptics.  Mölnlycke employs around 8,700 people. The headquarters are in Gothenburg, Sweden, and the company operates in more than 100 countries worldwide. Mölnlycke is owned by Patricia Industries AB, which is part of Investor AB, an engaged owner of high-quality, global companies founded by the Wallenberg family in 1916. www.molnlycke.com 

Being born with a cleft lip or palate is more than just a cosmetic problem. Many children have issues eating or speaking. They can grow up isolated, unable to socialise and deprived of opportunities. The Philippines has one of the highest incidences of cleft palate and cleft lip in the world. A simple surgical procedure can correct cleft problems. But access to healthcare is low in the country, particularly for people living outside the two main islands, and there is a need to enhance the specialist cleft care skills of healthcare professionals. 10,000 surgeries in three years The centre, which is planned to open in Q4 2021, will serve the 27 million people who live on Cebu or one of the 150+ surrounding islands. In its first three years, Operation Smile and Mölnlycke estimate that the centre will support up to 10,000 surgeries, via a hub and spokes model in the community. More than 26,000 patients will receive consultations and 1,800 community health workers will be trained – alongside 400 Operation Smile volunteers and hospital staff. Supporting with funds, products and expertise Mölnlycke has committed to an initial three-year partnership agreement to support the centre at Cebu. In addition to funds, the company will donate products, train healthcare professionals in infection prevention and provide logistics support. As expertise within Cebu and the surrounding area grows, the ambition is for the centre to become less reliant on direct support and more self-sufficient. Zlatko cleft centre Quote Follow #Cebu10000 #Cebu10000 is the first time Mölnlycke has supported healthcare infrastructure and marks a significant step-change in the company’s relationship with its global charity partner Operation Smile. Since 2004, when Mölnlycke began its support of Operation Smile, the company has donated funds, volunteer time and more than 1.5 million pairs of Biogel® surgical gloves to support cleft procedures. A model of cleft care Bill Magee Cleft centre Quote   Press contact Liz Neal Director of Communications Email: liz.neal@molnlycke.com Phone: +44 7787432560   About Mölnlycke Mölnlycke Health Care is a world-leading MedTech company that specialises in innovative solutions for wound care and surgical procedures. Mölnlycke products and solutions are used daily by hospitals, health care providers and patients in over 100 countries around the world. Founded in 1849, Mölnlycke is owned by Investor AB and headquartered in Sweden. www.molnlycke.com